Phaseline

Targets › TRA

TRA (M1-specific T cell receptor alpha chain): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2027.

The alpha chain of TRAV27*01J42*01C*01/TRBV19*01J2S7*01C*02 alpha-beta T cell receptor (TR) clonotype that is specific for HLA-A*02:01-restricted M/matrix protein 1 immunodominant epitope GILGFVFTL of influenza A virus (IAV). Classified as a public TR clonotype, it is preferentially selected in effector memory CD8-positive T cells among multiple HLA-A*02:01 carriers and confers long-lived immunity against IAV…. (UniProt, P0DSE1)

Open in Phaseline: the race on TRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jonsson Comprehensive Cancer CenterNY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
T cell receptor (TCR) gene-engineered lymphocytes targeting NY-ESO-1 antigen
TRA, TRBPhase 2Malignant NeoplasmNov 2027
University of ChicagoNY-ESO-1 TCR/ dnTGFβRII
Gene-modified T cells expressing NY-ESO-1-specific T cell receptor and dominant-negative T
TRA, TRB, TGFBR2Phase 1Ovarian CancerDec 2031

Conditions

Ovarian Cancer (1) Malignant Neoplasm (1)

Modalities

mixed (2)

Companies

University of Chicago (1) Jonsson Comprehensive Cancer Center (1)

Related targets

TRB (2) TGFBR2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.